Gold nanoparticles in theranostic oncology: current state-of-the-art
Sohail Akhter(Teva Pharmaceuticals (United Kingdom)), Robbert J. Kok(Utrecht University), Mohammad Zaki Ahmad(Najran University), Farhan Jalees Ahmad(Jamia Hamdard), Gert Storm(Yong In University)
Cited by 140
Related Papers
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
|Frontiers in Pharmacology|2018|937
Sheddable Coatings for Long-Circulating Nanoparticles
|Pharmaceutical Research|2007|549
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
|Drug Resistance Updates|2005|461
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
|Advanced Drug Delivery Reviews|2013|396
Diverse origins of the myofibroblast—implications for kidney fibrosis
|Nature Reviews Nephrology|2015|305